Napo Pharmaceuticals, a Jaguar Health, Inc. (Nasdaq:JAGX) family company, has recapped a panel on pediatric intestinal failure held at the 2nd Best of Elite Ped-GI meeting in Dubai, United Arab Emirates. The October 30, 2026 discussion examined microvillus inclusion disease (MVID), short bowel syndrome with intestinal failure (SBS-IF), and investigations of oral crofelemer as an adjunct to parenteral support.
#Panel focused on intestinal failure and parenteral nutrition
The session, titled “Intestinal Barrier: Beyond Total Parenteral Nutrition (TPN),” formed part of a meeting focused on clinical knowledge and practices in pediatric gastroenterology and nutrition. Napo was one of the meeting’s sponsors.
Participants included Dr. Mohamad Miqdady, Chief of Pediatric Gastroenterology at Sheikh Khalifa Medical City in Abu Dhabi; Dr. Christos Tzivinikos, a professor at Al Jalila Children’s Hospital in Dubai; and Pravin Chaturvedi, PhD, Napo’s and Jaguar’s Chief Scientific Officer and Chair of the Scientific Advisory Board.
The panel addressed the clinical challenges associated with pediatric intestinal failure and the burden of long-term parenteral nutrition. Patients with intestinal failure may be unable to absorb sufficient nutrients, electrolytes and fluids by mouth. The company said supportive treatment can involve total parenteral nutrition, with or without additional intravenous fluids, for up to seven days per week and up to 20+ hours per day.
Napo also described parenteral support as lifesaving but associated with serious, sometimes fatal complications.
Panelists reviewed the rationale for studying Napo’s liquid oral crofelemer formulation to reduce intestinal fluid losses. The discussion included pediatric MVID and SBS-IF patients who had received liquid oral crofelemer for >1 year.
According to the company, the findings included lower parenteral support requirements when adjusted for body weight, along with improvements in weight and stature growth parameters. Napo also said ongoing investigations showed substantial reductions in weekly parenteral support needs and in support normalized to body weight, with no significant clinical or laboratory abnormalities.
The company said disease heterogeneity remains significant. Panelists discussed an ongoing randomized, double-blind, placebo-controlled crossover study in MVID patients, which Napo said is required to support regulatory requirements.
#Development programme and planned regulatory filing
Napo said it remains focused on a global development programme evaluating oral crofelemer as adjunctive therapy to parenteral support for rare intestinal-failure diseases, including MVID and SBS-IF.
The company also referred to data presented in June 2026 at the 58 th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting in Lille, France. The data came from ongoing investigations of liquid oral crofelemer in pediatric patients with intestinal failure caused by MVID and SBS-IF.
Napo expects its pediatric MVID programme to provide clinical milestones supporting a planned New Drug Application filing for MVID in mid-2027. Jaguar identified this expectation and the planned filing as forward-looking statements based on current expectations and projections. The company said these statements are subject to risks, uncertainties and assumptions, including some beyond its control, and noted that the forward-looking statements are predictions.
Jaguar Health is a commercial-stage pharmaceuticals company developing proprietary prescription medicines sustainably derived from rainforest plants for people and animals with gastrointestinal distress. Its family companies, Napo Pharmaceuticals and Napo Therapeutics S.p.A., are focused on developing and commercializing crofelemer powder for oral solution for rare and orphan gastrointestinal disorders involving intestinal failure, including MVID and short bowel syndrome.
Napo recapped an October 30, 2026 panel on pediatric intestinal failure at a gastroenterology meeting in Dubai.
The discussion covered MVID, SBS-IF, parenteral support and investigations of liquid oral crofelemer.
The company reported lower parenteral support requirements normalized to body weight and improved growth parameters in patients receiving liquid oral crofelemer for >1 year.
An ongoing randomized, double-blind, placebo-controlled crossover study in MVID patients is described as required to support regulatory requirements.
Napo expects its pediatric MVID programme to support a planned NDA filing in mid-2027, subject to the risks and uncertainties identified by Jaguar.
Jaguar Health, Inc. said its family company Napo Pharmaceuticals provided a recap of the panel discussion titled “Intestinal Barrier: Beyond Total Parenteral Nutrition (TPN)”. The discussion took place at the 2nd Best of Elite Ped-GI meeting in Dubai, United Arab Emirates, and Napo was one of the meeting’s sponsors.
The panel discussion took place on October 30, 2026, at the 2nd Best of Elite Ped-GI meeting in Dubai. Jaguar Health, Inc. issued the recap on November 2, 2026.
The panellists were Dr. Mohamad Miqdady, Chief of Pediatric Gastroenterology at Sheikh Khalifa Medical City in Abu Dhabi; Dr. Christos Tzivinikos, Professor at Al Jalila Children’s Hospital in Dubai; and Pravin Chaturvedi, PhD, Napo’s and Jaguar’s Chief Scientific Officer and Chair of the Scientific Advisory Board.
The panel addressed the clinical challenges of paediatric intestinal failure, including microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), as well as the burden of long-term dependence on parenteral nutrition. It also discussed the scientific rationale for investigating liquid oral crofelemer to reduce intestinal fluid losses.
Jaguar Health, Inc. reported that findings from paediatric MVID and SBS-IF patients receiving liquid oral crofelemer for >1 year showed reductions in parenteral support when normalised to body weight and improvements in weight and stature growth parameters. The company also said ongoing investigations demonstrated substantial reductions in weekly parenteral support needs and in parenteral support normalised to body weight, with no significant clinical or laboratory abnormalities.
Jaguar Health, Inc. said patients with intestinal failure, including paediatric MVID and paediatric and adults with Type 1 SBS, cannot adequately absorb nutrients, electrolytes and fluids orally. They therefore require lifelong supportive therapy with total parenteral nutrition, with or without supplemental intravenous fluids, for up to seven days per week and up to 20+ hours per day.
Jaguar Health, Inc. said parenteral support is supportive and lifesaving but is associated with serious, sometimes fatal complications. The company described the long-term dependence on parenteral nutrition as a significant burden for patients with intestinal failure.
Jaguar Health, Inc. said an ongoing randomised, double-blind, placebo-controlled crossover study in MVID patients is important because of the significant heterogeneity of the disease and is required to support regulatory requirements for the company.
Jaguar Health, Inc. said Napo remains focused on its ongoing global development programme for oral crofelemer as adjunctive therapy to parenteral support for rare intestinal-failure diseases, including MVID and SBS-IF. The programme involves crofelemer powder for oral solution.
Jaguar Health, Inc. said Napo’s paediatric MVID programme is expected to provide clinical milestones that will support its planned New Drug Application filing for MVID, with the company targeting an NDA filing in mid-2027. The company identified these statements as forward-looking predictions subject to risks, uncertainties and assumptions, some of which are beyond its control.
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Its family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on developing and commercialising crofelemer powder for oral solution for rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.
Jaguar Health, Inc. is identified in the source as trading on Nasdaq under the ticker symbol Nasdaq:JAGX.
Jaguar Health, Inc. said data from ongoing investigational studies of liquid oral crofelemer in paediatric patients with intestinal failure due to MVID and SBS-IF was presented in June 2026 at the 58 th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting in Lille, France.